March, 2026 – Eurofarma, one of the largest Latin American pharmaceutical companies and a reference in innovation within the sector, announces the expansion of access to cenobamate, a next‑generation reference medication for the treatment of focal epilepsy. The product has just obtained marketing approval from Anvisa in Brazil, joining Argentina, Chile, Ecuador and Peru as the first markets to receive regulatory authorization. Eurofarma also plans to expand availability to an additional 12 countries in the region. 

Focal epilepsy affects millions of people in Latin America, and many patients continue to experience seizures despite currently available therapies, significantly impacting their quality of life and that of their families. The introduction of cenobamate is the result of a licensing agreement with SK Biopharmaceuticals, and the medication has already been available in the United States (2019) and Europe (2021) for more than five years, generating substantial impact on patients’ lives. 

“Treatment with cenobamate can drastically reduce epileptic seizures even in patients with drug‑resistant epilepsy, offering important quality‑of‑life benefits for people living with epilepsy in Latin America. Patients who previously had no access to innovative medications like this, or relied on exceptional importation, now have access to a new therapeutic option. Approval by Anvisa is also an important milestone reinforcing our commitment to investing in innovative, high‑clinical‑value solutions with strong social impact,” stated João Siffert, Vice President of Innovation at Eurofarma. 
 
Efficacy results

One in every five patients achieved seizure freedom in pivotal clinical trials. With its innovative mechanism of action, cenobamate demonstrated unprecedented efficacy in treating drug‑resistant focal epilepsy. In adjunctive therapy, patients treated with 400 mg/day achieved a median 65% reduction in focal seizure frequency during the maintenance phase¹, while the 200 mg/day dose resulted in a 55.6% median reduction², with consistent findings across both studies¹,². Notably, one in five patients (21%¹ and 28.3%²) achieved seizure freedom—an outcome rarely observed with other pharmacological therapies. For context, after three lines of conventional antiseizure medication therapy, only 4% of patients reach similar outcomes³. 

Recent real‑world evidence further supports these results. A 2025 study showed that 79.6% of patients experienced a ≥50% reduction in seizure frequency after one year of treatment, and 36.6% achieved seizure freedom. These high indices remained stable after two years: 80% for ≥50% reduction and 30.9% achieving seizure freedom. Treatment adherence was high, with significant reductions in the number and dose of concomitant medications, simplifying therapeutic regimens.⁴ 
 
Epilepsy: a public health challenge in Latin America 

Epilepsy is one of the most prevalent chronic neurological diseases worldwide and represents a major public health challenge. In Latin America and the Caribbean, the region is home to more than six million people with active epilepsy, and over 60% do not receive adequate treatment due to barriers such as late diagnosis, limited access to specialists and restricted availability of innovative therapies.⁵–⁷ As a result, epilepsy remains associated with high levels of disability, social stigma and reduced quality of life. 

Expanding access to innovative medications such as cenobamate is essential to reducing the existing therapeutic gap, especially among patients with difficult‑to‑control epilepsy. The arrival of new therapeutic options in Latin America represents a significant step forward for the healthcare ecosystem and for millions of people living with epilepsy.